TABLE 2.
Susceptibility profiles of resistant mutants obtained by plating detached biofilms from sequential treatments
| Strain and treatment | MIC (mg/liter)a |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TIC | P/T | CAZ | FEP | ATM | C/T | IMI | MER | CIP | TOB | AMI | CST | |
| PAO1 | 8 | 4/4 | 1 | 1 | 2 | 0.5/4 | 4 | 1 | 0.25 | 0.5 | 4 | 2 |
| 146-HSE | >512 | >256/4 | 2 | 32 | 2 | 4/4 | 1 | 1 | 16 | 4 | 32 | 2 |
| T/A/T | ||||||||||||
| MHA | >512 | >256/4 | 8 | >64 | 32 | 4/4 | 2 | 4 | 16 | 8 | 32 | 2 |
| 4× MIC ATM | >512 | >256/4 | 8 | >64 | 128 | 4/4 | 4 | 4 | 16 | 16 | 32 | 2 |
| 16× MIC ATM | >512 | >256/4 | 8 | >64 | 64 | 4/4 | 2 | 4 | 16 | 32 | 64 | 2 |
| 4× MIC TOB | >512 | >256/4 | 8 | >64 | 64 | 4/4 | 2 | 4 | 16 | 32 | 64 | 2 |
| 16× MIC TOB | >512 | >256/4 | 8 | >64 | 64 | 4/4 | 2 | 4 | 16 | >32 | 64 | 8 |
| A/T/A | ||||||||||||
| MHA | >512 | >256/4 | 8 | >64 | 64 | 4/4 | 4 | 4 | >16 | 32 | 32 | 4 |
| 4× MIC ATM | >512 | >256/4 | 8 | >64 | 64 | 4/4 | 2 | 4 | 16 | 32 | 32 | 2 |
| 16× MIC ATM | >512 | >256/4 | 16 | >64 | >128 | 4/4 | 4 | 4 | 16 | 16 | 32 | 4 |
| 4× MIC TOB | >512 | >256/4 | 8 | >64 | 64 | 4/4 | 2 | 2 | 16 | 32 | 64 | 4 |
a
TIC, ticarcillin; P/T, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; C/T, ceftolozane-tazobactam; IMI, imipenem; MER, meropenem; CIP, ciprofloxacin; TOB, tobramycin; AMI, amikacin; CST, colistin.